Nomenclature for alleles of the thiopurine methyltransferase gene

The drug-metabolizing enzyme thiopurine methyltransferase (TPMT) has become one of the best examples of pharmacogenomics to be translated into routine clinical practice. TPMT metabolizes the thiopurines 6-mercaptopurine, 6-thioguanine, and azathioprine, drugs that are widely used for treatment of acute leukemias, inflammatory bowel diseases, and other disorders of immune regulation. Since the discovery of genetic polymorphisms in the TPMT gene, many sequence variants that cause a decreased enzyme activity have been identified and characterized. Increasingly, to optimize dose, pretreatment determination of TPMT status before commencing thiopurine therapy is now routine in many countries. Novel TPMT sequence variants are currently numbered sequentially using PubMed as a source of information; however, this has caused some problems as exemplified by two instances in which authors’ articles appeared on PubMed at the same time, resulting in the same allele numbers given to different polymorphisms. Hence, there is an urgent need to establish an order and consensus to the numbering of known and novel TPMT sequence variants. To address this problem, a TPMT nomenclature committee was formed in 2010, to define the nomenclature and numbering of novel variants for the TPMT gene. A website (http://www.imh.liu.se/tpmtalleles) serves as a platform for this work. Researchers are encouraged to submit novel TPMT alleles to the committee for designation and reservation of unique allele numbers. The committee has decided to renumber two alleles: nucleotide position 106 (G>A) from TPMT*24 to TPMT*30 and position 611 (T>C, rs79901429) from TPMT*28 to TPMT*31. Nomenclature for all other known alleles remains unchanged.

[1]  R. Wade,et al.  Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. , 2013, British journal of clinical pharmacology.

[2]  R. Mantegazza,et al.  A New Thiopurine S‐Methyltransferase Haplotype Associated With Intolerance to Azathioprine , 2013, Journal of clinical pharmacology.

[3]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[4]  Claudio J. Verzilli,et al.  An Abundance of Rare Functional Variants in 202 Drug Target Genes Sequenced in 14,002 People , 2012, Science.

[5]  A. Marinaki,et al.  Novel thiopurine methyltransferase variant TPMT*28 results in a misdiagnosis of TPMT deficiency. , 2011, Inflammatory bowel diseases.

[6]  J. Lo-Guidice,et al.  Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response? , 2011, Pharmacogenetics and genomics.

[7]  M. Relling,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapeutics.

[8]  C. Peterson,et al.  Characterization of a novel sequence variant, TPMT*28, in the human thiopurine methyltransferase gene , 2010, Pharmacogenetics and genomics.

[9]  R. Altman,et al.  Very important pharmacogene summary: thiopurine S-methyltransferase. , 2010, Pharmacogenetics and genomics.

[10]  S. Coulthard,et al.  Thiopurines: factors influencing toxicity and response. , 2010, Biochemical pharmacology.

[11]  R. Weinshilboum,et al.  Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme. , 2010, Biochemical pharmacology.

[12]  A. Yeoh,et al.  TPMT*26 (208F-->L), a novel mutation detected in a Chinese. , 2009, British journal of clinical pharmacology.

[13]  M. Hiratsuka,et al.  Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2 – *24) , 2008, Pharmacogenetics and genomics.

[14]  M. Eichelbaum,et al.  Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. , 2008, Clinical chemistry.

[15]  M. Loriot,et al.  Characterisation of novel defective thiopurine S-methyltransferase allelic variants. , 2008, Biochemical pharmacology.

[16]  P. Söderkvist,et al.  Explaining TPMT genotype/phenotype discrepancy by haplotyping of TPMT*3A and identification of a novel sequence variant, TPMT*23 , 2007, Pharmacogenetics and genomics.

[17]  A. Amorim,et al.  Do the distribution patterns of polymorphisms at the thiopurine S-methyltransferase locus in sub-Saharan populations need revision? Hints from Cabinda and Mozambique , 2007, European Journal of Clinical Pharmacology.

[18]  M. Eichelbaum,et al.  Three novel thiopurine S‐methyltransferase allelic variants (TPMT*20, *21, *22) – association with decreased enzyme function , 2006, Human mutation.

[19]  P. Karran.  Thiopurines, DNA damage, DNA repair and therapy-related cancer. , 2006, British medical bulletin.

[20]  M. Relling,et al.  Thiopurine methyltransferase in acute lymphoblastic leukemia. , 2006, Blood.

[21]  M. Neurath,et al.  Azathioprine Suppresses Ezrin-Radixin-Moesin-Dependent T Cell-APC Conjugation through Inhibition of Vav Guanosine Exchange Activity on Rac Proteins , 2006, The Journal of Immunology.

[22]  R. Weinshilboum,et al.  Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics , 2005, Pharmacogenetics and genomics.

[23]  M. Schrappe,et al.  Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. , 2005, JAMA.

[24]  J. Lo-Guidice,et al.  Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT*16 and TPMT*19. , 2005, Biochemical pharmacology.

[25]  Michel Eichelbaum,et al.  Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. , 2004, Pharmacogenetics.

[26]  P. Söderkvist,et al.  Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. , 2004, Pharmacogenetics.

[27]  C. Spire,et al.  In vitro characterization of four novel non-functional variants of the thiopurine S-methyltransferase. , 2003, Biochemical and biophysical research communications.

[28]  M. Schrappe,et al.  A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALL , 2003, Leukemia.

[29]  M. Neurath,et al.  CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. , 2003, The Journal of clinical investigation.

[30]  A. Hall,et al.  The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. , 2002, Molecular pharmacology.

[31]  Mathew W. Wright,et al.  Guidelines for human gene nomenclature. , 2002, Genomics.

[32]  M. Relling,et al.  Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. , 2001, Cancer research.

[33]  S. Antonarakis,et al.  Nomenclature for the description of human sequence variations , 2001, Human Genetics.

[34]  B. Bonaz,et al.  Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.

[35]  H. McLeod,et al.  Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. , 1999, Pharmacogenetics.

[36]  M. Relling,et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.

[37]  M. Relling,et al.  Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. , 1999, Human molecular genetics.

[38]  H. McLeod,et al.  Thiopurine methyltransferase alleles in British and Ghanaian populations. , 1999, Human molecular genetics.

[39]  J. Lafitte,et al.  Genotypic and phenotypic analysis of the polymorphic thiopurine S‐methyltransferase gene (TPMT) in a European population , 1998, British journal of pharmacology.

[40]  S Povey,et al.  Guidelines for human gene nomenclature (1997). HUGO Nomenclature Committee. , 1997, Genomics.

[41]  R. Weinshilboum,et al.  Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms , 1997, Clinical pharmacology and therapeutics.

[42]  W. Evans,et al.  Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Ching-Hon Pui,et al.  Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance , 1997, Annals of Internal Medicine.

[44]  W. Evans,et al.  Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. , 1996, American journal of human genetics.

[45]  R. Weinshilboum,et al.  Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[46]  M. Relling,et al.  A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Lilleyman,et al.  Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. , 1993, Archives of disease in childhood.

[48]  W. Evans,et al.  Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. , 1991, The Journal of pediatrics.

[49]  R. Weinshilboum,et al.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia , 1990, The Lancet.

[50]  R. Weinshilboum,et al.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.

[51]  C. P. Rhoads,et al.  Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. , 1953, Blood.

[52]  G. Hitchings,et al.  Antagonists of nucleic acid derivatives. VI. Purines. , 1951, The Journal of biological chemistry.

[53]  E. Koay,et al.  Detection of a novel single nucleotide polymorphism of the human thiopurine s-methyltransferase gene in a Chinese individual. , 2012, Drug metabolism and pharmacokinetics.

[54]  Federação Brasileira de Gastroenterologia,et al.  [Gastroesophageal reflux disease: non-pharmacological treatment]. , 2012, Revista da Associacao Medica Brasileira.

[55]  M. Hiratsuka,et al.  Three novel single nucleotide polymorphisms of the human thiopurine S-methyltransferase gene in Japanese individuals. , 2006, Drug metabolism and pharmacokinetics.

[56]  G. Hitchings,et al.  ANTAGONISTS OF NUCLEIC ACID DERIVATIVES , 2002 .

[57]  D. Marez,et al.  Detection of known and new mutations in the thiopurine S‐methyltransferase gene by single‐strand conformation polymorphism analysis , 1998, Human mutation.

[58]  S. Antonarakis.  Recommendations for a nomenclature system for human gene mutations , 1998 .

[59]  S. Antonarakis.  Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. , 1998, Human mutation.

[60]  R. Weinshilboum,et al.  Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. , 1996, DNA and cell biology.

[61]  R. Weinshilboum,et al.  Human thiopurine methyltransferase pharmacogenetics: Identification of a novel variant allele , 1996 .